Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Necrotizing Enterocolitis: early-phase trial registry
3 of 15 indexed Necrotizing Enterocolitis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 3 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Necrotizing Enterocolitis: 15 US clinical trials tracked, 3 recruiting.
Necrotizing Enterocolitis is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Infant Bacterial Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition necrotizing-enterocolitis
OPEN 3 | RECR 20% | LATE 1 | EARLY 6 | RANK #1140 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Necrotizing Enterocolitis lists 3 open slots (20% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Necrotizing Enterocolitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Necrotizing Enterocolitis is recruiting below its size-band peers.
3 of 15 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Necrotizing Enterocolitis trials is spread across many organizations.
Infant Bacterial Therapeutics accounts for 2 of 15 trials (13.3%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Necrotizing Enterocolitis enrolment sits around 130 participants.
Median target enrolment is 130 among the 15 trials that report a genuine target (sentinel values excluded). 6 of those (40%) plan for fewer than 100 participants.
-
Necrotizing Enterocolitis splits between interventional and observational designs.
10 interventional and 5 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Early Predictors of Necrotizing Enterocolitis in Neonates
Nationwide Children's Hospital
NCT03210831
Early Routine vs. Selective Human Milk Fortification in Extremely Preterm Infants
Crouse Hospital
NCT04284280
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis
Noveome Biotherapeutics, formerly Stemnion
NCT06315738
IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study
Infant Bacterial Therapeutics
NCT03978000
RBC Irradiation, Anemia and Gut Injury
Emory University
NCT02741648
A Cohort Study of the Intestinal Microbiota of Premature Infants
University of California, Davis
NCT03717584
RIC-NEC Randomized Controlled Trial
The Hospital for Sick Children
NCT05279664
Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus
University of California, San Francisco
NCT01958320
Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections
The Emmes Company
NCT00621192
Comparison of Two Surgical Treatments for Necrotizing Enterocolitis in Human Infants
Yale University
NCT00252681
IBP-9414 for the Prevention of Necrotizing Enterocolitis
Infant Bacterial Therapeutics
NCT02472769
Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
University of Utah
NCT03551600
Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis
University of Utah
NCT01735578
Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy
Wake Forest University
NCT01306838
Collaborative Research Group for Necrotizing Enterocolitis
Washington University School of Medicine
NCT00828451
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Necrotizing Enterocolitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Necrotizing Enterocolitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Necrotizing Enterocolitis page
15 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Necrotizing Enterocolitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Infant Bacterial Therapeutics sponsors the most Necrotizing Enterocolitis trials on record, review their full trial history before evaluating a specific study. See Infant Bacterial Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Necrotizing Enterocolitis condition card totals 15 registered trials; most-linked intervention IBP-9414; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.